Tryptamine Therapeutics (ASX:TYP) entered into an exclusive biomarker development agreement with Robin Carhart-Harris, the Chair of the firm's scientific advisory board and Pedro Mediano, a professor at the Imperial College London, to develop a proprietary electroencephalogram-based platform to support the clinical development of its TRP-8803 drug candidate, according to a Thursday Australian bourse filing.

Carhart-Harris, Mediano, and the firm will work to develop a proprietary electroencephalogram-based biomarker platform, leveraging real-time cortical entropy to predict and optimize therapeutic outcomes before, during, and after intravenous administration of TRP-8803.

This could allow clinicians to identify patients that may best respond to psychedelic intervention and modulate dosing in real time to reach the optimal neuroplasticity window.

The agreement has an initial one-year term with an option to extend for another year, under which the firm will pay $100,000 per annum for the services provided. It will also grant, subject to shareholder approval, 1,000,000 options each to Carhart-Harris and Mediano, exercisable at $0.08 and expiring two years from the date of issue.